May 10 | News
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g.
|
May 1 | News
April proved to be a big month for M&A activity as companies announced more than $29 billion in agreed upon transactions during the month, the bulk of which occurred during the final week.
|
Apr 27 | News
Watson Pharmaceuticals, Inc. today announced that it has refined and expanded the responsibilities of its senior executive team, in recognition of the company's continued global expansion, particularly following the announcement of Watson's intention to acquire Actavis.
|
Apr 20 | News
Watson Pharmaceuticals, Inc. today announced that it has launched an authorized generic version of FORTAMET (metformin hydrochloride extended-release tablets) as part of an agreement with Shionogi, Inc.
|
Apr 19 | News
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Metformin Hydrochloride Extended-release Tablets USP, 1000 mg. Watson's Metformin Hydrochloride Extended-release Tablets are a generic version of Depomed, Inc.'s Glumetza.
|
Apr 4 | News
Watson Pharmaceuticals, Inc. today confirmed that the United States District Court for the District of Delaware has ruled that the asserted claims of United States Patent Nos. 7,410,978 (the '978 Patent), 7,759,359 (the '359 Patent), 7,781,448 (the '448 Patent), 7,781,449 (the '449 Patent) and 7,763,635 (the '635 Patent) for Sanctura XR (trospium chloride extended-release capsules) are invalid.
|
Feb 27 | News
Watson Pharmaceuticals, Inc. and Columbia Laboratories, Inc. today confirmed that, as expected, Watson has received a complete response letter from the FDA for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.
|
Feb 13 | News
Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced that Columbia has transferred the new drug application for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy (NDA 22-139) to Watson.
|
Feb 9 | News
Watson Pharmaceuticals CEO Paul Bisaro said the company has around $6 billion to spend on acquisitions as it looks to buy brand-name drug assets, signaling a move away from the company's focus on generic medicines, Bloomberg reported Thursday.
|
Feb 8 | News
Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.
|